{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T09:20:41Z","timestamp":1791537641415,"version":"4.3.4"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T00:00:00Z","timestamp":1531958400000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The gut\u2013liver axis is increasingly considered to play a vital part in the progression of chronic inflammatory gut and liver diseases. Hence, a detailed understanding of the local and systemic regulatory mechanisms is crucial to develop novel therapeutic approaches. In this review, we discuss in-depth the roles of regulatory T cells (Tregs) and mucosal-associated invariant T cells (MAITs) within the context of inflammatory bowel disease, primary sclerosing cholangitis, and non-alcoholic steatohepatitis. Tregs are crucial in maintaining peripheral tolerance and preventing autoimmunity. MAIT cells have a unique ability to rapidly recognize microbial metabolites and mount a local immune response and act as a \u2018biliary firewall\u2019 at the gut and biliary epithelial barrier. We also outline how current knowledge can be exploited to develop novel therapies to control the propagation of chronic gut- and liver-related inflammatory and autoimmune conditions. We specifically focus on the nature of the Tregs\u2019 cell therapy product and outline an adjunctive role for low-dose IL-2. All in all, it is clear that translational immunology is at crucial crossroads. The success of ongoing clinical trials in cellular therapies for inflammatory gut and liver conditions could revolutionize the treatment of these conditions and the lives of our patients in the coming years.<\/jats:p>","DOI":"10.1007\/s12072-018-9882-x","type":"journal-article","created":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T13:09:43Z","timestamp":1532005783000},"page":"305-314","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Linking the gut and liver: crosstalk between regulatory T cells and mucosa-associated invariant T cells"],"prefix":"10.1007","volume":"12","author":[{"given":"Muhammad","family":"Atif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suz","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye H.","family":"Oo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,19]]},"reference":[{"issue":"3","key":"9882_CR1","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00394-017-1524-x","volume":"57","author":"F de Faria Ghetti","year":"2018","unstructured":"de Faria Ghetti F, et al. Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis. Eur J Nutr 2018;57(3):861\u2013876","journal-title":"Eur J Nutr"},{"issue":"4","key":"9882_CR2","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/S1665-2681(19)31457-7","volume":"11","author":"MV Machado","year":"2012","unstructured":"Machado MV, Cortez-Pinto H. Gut microbiota and nonalcoholic fatty liver disease. Ann Hepatol 2012;11(4):440\u2013449","journal-title":"Ann Hepatol"},{"issue":"19","key":"9882_CR3","doi-asserted-by":"publisher","first-page":"e94416","DOI":"10.1172\/jci.insight.94416","volume":"2","author":"C Acharya","year":"2017","unstructured":"Acharya C, Sahingur SE, Bajaj JS. Microbiota, cirrhosis, and the emerging oral-gut-liver axis. JCI Insight 2017;2(19):e94416","journal-title":"JCI Insight"},{"issue":"4","key":"9882_CR4","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.crohns.2013.01.010","volume":"7","author":"J Burisch","year":"2013","unstructured":"Burisch J, et al. The burden of inflammatory bowel disease in Europe. J Crohns Colitis 2013;7(4):322\u2013337","journal-title":"J Crohns Colitis"},{"issue":"3","key":"9882_CR5","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/hep.28356","volume":"63","author":"J Boursier","year":"2016","unstructured":"Boursier J, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 2016;63(3):764\u2013775","journal-title":"Hepatology"},{"issue":"5","key":"9882_CR6","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.jhep.2013.05.034","volume":"59","author":"YH Oo","year":"2013","unstructured":"Oo YH, Sakaguchi S. Regulatory T-cell directed therapies in liver diseases. J Hepatol 2013;59(5):1127\u20131134","journal-title":"J Hepatol"},{"issue":"1","key":"9882_CR7","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.transproceed.2004.12.259","volume":"37","author":"A Yoshizawa","year":"2005","unstructured":"Yoshizawa A, et al. The roles of CD25+CD4+ regulatory T cells in operational tolerance after living donor liver transplantation. Transplant Proc 2005;37(1):37\u201339","journal-title":"Transplant Proc"},{"issue":"5","key":"9882_CR8","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.smim.2013.09.002","volume":"25","author":"J Bollrath","year":"2013","unstructured":"Bollrath J, Powrie FM. Controlling the frontier: regulatory T-cells and intestinal homeostasis. Semin Immunol 2013;25(5):352\u2013357","journal-title":"Semin Immunol"},{"issue":"40","key":"9882_CR9","doi-asserted-by":"publisher","first-page":"11236","DOI":"10.3748\/wjg.v21.i40.11236","volume":"21","author":"JD Lord","year":"2015","unstructured":"Lord JD. Promises and paradoxes of regulatory T-cells in inflammatory bowel disease. World J Gastroenterol 2015;21(40):11236\u201311245","journal-title":"World J Gastroenterol"},{"issue":"1","key":"9882_CR10","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1365-2249.2007.03356.x","volume":"148","author":"B Afzali","year":"2007","unstructured":"Afzali B, et al. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 2007;148(1):32\u201346","journal-title":"Clin Exp Immunol"},{"issue":"3","key":"9882_CR11","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.4049\/jimmunol.155.3.1151","volume":"155","author":"S Sakaguchi","year":"1995","unstructured":"Sakaguchi S, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155(3):1151\u20131164","journal-title":"J Immunol"},{"issue":"7426","key":"9882_CR12","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/nature11605","volume":"491","author":"L Kjer-Nielsen","year":"2012","unstructured":"Kjer-Nielsen L, et al. MR1 presents microbial vitamin B metabolites to MAIT cells. Nature 2012;491(7426):717\u2013723","journal-title":"Nature"},{"issue":"5","key":"9882_CR13","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.jhep.2015.12.017","volume":"64","author":"HC Jeffery","year":"2016","unstructured":"Jeffery HC, et al. Biliary epithelium and liver B cells exposed to bacteria activate intrahepatic MAIT cells through MR1. J Hepatol 2016;64(5):1118\u20131127","journal-title":"J Hepatol"},{"key":"9882_CR14","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3389\/fimmu.2015.00344","volume":"6","author":"RJ Napier","year":"2015","unstructured":"Napier RJ, et al. The role of mucosal associated invariant T cells in antimicrobial immunity. Front Immunol 2015;6:344","journal-title":"Front Immunol"},{"issue":"8","key":"9882_CR15","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1038\/cti.2016.51","volume":"5","author":"A Kurioka","year":"2016","unstructured":"Kurioka A, et al. MAIT cells: new guardians of the liver. Clin Transl Immunol 2016;5(8):e98","journal-title":"Clin Transl Immunol"},{"issue":"1","key":"9882_CR16","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1177\/2050640617708953","volume":"6","author":"J Torres","year":"2018","unstructured":"Torres J, et al. The gut microbiota, bile acids and their correlation in primary sclerosing cholangitis associated with inflammatory bowel disease. United Eur Gastroenterol J 2018;6(1):112\u2013122","journal-title":"United Eur Gastroenterol J"},{"issue":"1","key":"9882_CR17","doi-asserted-by":"publisher","first-page":"e1004559","DOI":"10.1371\/journal.ppat.1004559","volume":"11","author":"J Boursier","year":"2015","unstructured":"Boursier J, Diehl AM. Implication of gut microbiota in nonalcoholic fatty liver disease. PLoS Pathog 2015;11(1):e1004559","journal-title":"PLoS Pathog"},{"key":"9882_CR18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12876-014-0189-7","volume":"14","author":"SC Bischoff","year":"2014","unstructured":"Bischoff SC, et al. Intestinal permeability\u2014a new target for disease prevention and therapy. BMC Gastroenterol 2014;14:189","journal-title":"BMC Gastroenterol"},{"issue":"6","key":"9882_CR19","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1002\/hep.29676","volume":"67","author":"P Hartmann","year":"2018","unstructured":"Hartmann P, et al. Modulation of the intestinal bile acid-FXR-FGF15 axis improves alcoholic liver disease in mice. Hepatology 2018;67(6):2150\u20132166","journal-title":"Hepatology"},{"issue":"10","key":"9882_CR20","doi-asserted-by":"publisher","first-page":"3920","DOI":"10.1073\/pnas.0509592103","volume":"103","author":"T Inagaki","year":"2006","unstructured":"Inagaki T, et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci USA 2006;103(10):3920\u20133925","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"9882_CR21","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s00535-017-1400-8","volume":"53","author":"T Inamine","year":"2017","unstructured":"Inamine T, Schnabl B. Immunoglobulin A and liver diseases. J Gastroenterol 2017;53(6):691\u2013700","journal-title":"J Gastroenterol"},{"issue":"7","key":"9882_CR22","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1084\/jem.20060468","volume":"203","author":"N Seddiki","year":"2006","unstructured":"Seddiki N, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006;203(7):1693\u20131700","journal-title":"J Exp Med"},{"issue":"7","key":"9882_CR23","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1084\/jem.20060772","volume":"203","author":"W Liu","year":"2006","unstructured":"Liu W, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006;203(7):1701\u20131711","journal-title":"J Exp Med"},{"issue":"8","key":"9882_CR24","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1002\/eji.201243296","volume":"43","author":"B Afzali","year":"2013","unstructured":"Afzali B, et al. CD161 expression characterizes a subpopulation of human regulatory T cells that produces IL-17 in a STAT3-dependent manner. Eur J Immunol 2013;43(8):2043\u20132054","journal-title":"Eur J Immunol"},{"issue":"1","key":"9882_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3324\/haematol.2015.128934","volume":"101","author":"C Scotta","year":"2016","unstructured":"Scotta C, et al. Impact of immunosuppressive drugs on the therapeutic efficacy of ex vivo expanded human regulatory T cells. Haematologica 2016;101(1):91\u2013100","journal-title":"Haematologica"},{"issue":"12","key":"9882_CR26","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1097\/TP.0b013e31818febc4","volume":"86","author":"Y Li","year":"2008","unstructured":"Li Y, et al. The presence of Foxp3 expressing T cells within grafts of tolerant human liver transplant recipients. Transplantation 2008;86(12):1837\u20131843","journal-title":"Transplantation"},{"issue":"13","key":"9882_CR27","doi-asserted-by":"publisher","first-page":"5528","DOI":"10.1073\/pnas.88.13.5528","volume":"88","author":"VL Godfrey","year":"1991","unstructured":"Godfrey VL, et al. Fatal lymphoreticular disease in the scurfy (sf) mouse requires T cells that mature in a sf thymic environment: potential model for thymic education. Proc Natl Acad Sci USA 1991;88(13):5528\u20135532","journal-title":"Proc Natl Acad Sci USA"},{"key":"9882_CR28","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3389\/fimmu.2013.00169","volume":"4","author":"GA Povoleri","year":"2013","unstructured":"Povoleri GA, et al. Thymic versus induced regulatory T cells\u2014who regulates the regulators? Front Immunol 2013;4:169","journal-title":"Front Immunol"},{"issue":"1","key":"9882_CR29","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/imr.12160","volume":"259","author":"EM Shevach","year":"2014","unstructured":"Shevach EM, Thornton AM. tTregs, pTregs, and iTregs: similarities and differences. Immunol Rev 2014;259(1):88\u2013102","journal-title":"Immunol Rev"},{"issue":"12","key":"9882_CR30","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1097\/TP.0b013e3181f9960d","volume":"90","author":"H Nafady-Hego","year":"2010","unstructured":"Nafady-Hego H, et al. The generation of donor-specific CD4 +CD25++CD45RA+ naive regulatory T cells in operationally tolerant patients after pediatric living-donor liver transplantation. Transplantation 2010;90(12):1547\u20131555","journal-title":"Transplantation"},{"key":"9882_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trim.2016.04.005","volume":"36","author":"H Nafady-Hego","year":"2016","unstructured":"Nafady-Hego H, et al. Utility of CD127 combined with FOXP3 for identification of operational tolerance after liver transplantation. Transpl Immunol 2016;36:1\u20138","journal-title":"Transpl Immunol"},{"issue":"9301","key":"9882_CR32","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S0140-6736(02)07374-9","volume":"359","author":"AJ Grant","year":"2002","unstructured":"Grant AJ, et al. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of inflammatory bowel disease. Lancet 2002;359(9301):150\u2013157","journal-title":"Lancet"},{"issue":"3","key":"9882_CR33","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/cei.12804","volume":"185","author":"AL Rodriguez-Perea","year":"2016","unstructured":"Rodriguez-Perea AL, et al. Phenotypical characterization of regulatory T cells in humans and rodents. Clin Exp Immunol 2016;185(3):281\u2013291","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"9882_CR34","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/hep.28517","volume":"64","author":"YY Chen","year":"2016","unstructured":"Chen YY, et al. Human intrahepatic regulatory T cells are functional, require IL-2 from effector cells for survival, and are susceptible to Fas ligand-mediated apoptosis. Hepatology 2016;64(1):138\u2013150","journal-title":"Hepatology"},{"issue":"3","key":"9882_CR35","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.molmed.2007.01.003","volume":"13","author":"M Miyara","year":"2007","unstructured":"Miyara M, Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol Med 2007;13(3):108\u2013116","journal-title":"Trends Mol Med"},{"issue":"5","key":"9882_CR36","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","volume":"133","author":"S Sakaguchi","year":"2008","unstructured":"Sakaguchi S, et al. Regulatory T cells and immune tolerance. Cell 2008;133(5):775\u2013787","journal-title":"Cell"},{"issue":"5","key":"9882_CR37","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1136\/gutjnl-2017-314458","volume":"67","author":"A Riva","year":"2018","unstructured":"Riva A, et al. Mucosa-associated invariant T cells link intestinal immunity with antibacterial immune defects in alcoholic liver disease. Gut 2018;67(5):918\u2013930","journal-title":"Gut"},{"issue":"7","key":"9882_CR38","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.4049\/jimmunol.1203218","volume":"190","author":"XZ Tang","year":"2013","unstructured":"Tang XZ, et al. IL-7 licenses activation of human liver intrasinusoidal mucosal-associated invariant T cells. J Immunol 2013;190(7):3142\u20133152","journal-title":"J Immunol"},{"issue":"3","key":"9882_CR39","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s12275-018-8049-8","volume":"56","author":"T Eom","year":"2018","unstructured":"Eom T, et al. Current understanding of microbiota- and dietary-therapies for treating inflammatory bowel disease. J Microbiol 2018;56(3):189\u2013198","journal-title":"J Microbiol"},{"issue":"1","key":"9882_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cld.2015.08.012","volume":"20","author":"B Eksteen","year":"2016","unstructured":"Eksteen B. The gut\u2013liver axis in primary sclerosing cholangitis. Clin Liver Dis 2016;20(1):1\u201314","journal-title":"Clin Liver Dis"},{"issue":"5","key":"9882_CR41","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.jhep.2016.02.003","volume":"64","author":"A Toubal","year":"2016","unstructured":"Toubal A, Lehuen A. Lights on MAIT cells, a new immune player in liver diseases. J Hepatol 2016;64(5):1008\u20131010","journal-title":"J Hepatol"},{"key":"9882_CR42","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.3389\/fimmu.2017.01837","volume":"8","author":"L Ghazarian","year":"2017","unstructured":"Ghazarian L, Caillat-Zucman S, Houdouin V. Mucosal-associated invariant T cell interactions with commensal and pathogenic bacteria: potential role in antimicrobial immunity in the child. Front Immunol 2017;8:1837","journal-title":"Front Immunol"},{"issue":"8\u20139","key":"9882_CR43","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.micinf.2011.03.007","volume":"13","author":"MC Gold","year":"2011","unstructured":"Gold MC, Lewinsohn DM. Mucosal associated invariant T cells and the immune response to infection. Microbes Infect 2011;13(8\u20139):742\u2013748","journal-title":"Microbes Infect"},{"key":"9882_CR44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1476-9255-7-15","volume":"7","author":"AL Harte","year":"2010","unstructured":"Harte AL, et al. Elevated endotoxin levels in non-alcoholic fatty liver disease. J Inflamm (Lond) 2010;7:15","journal-title":"J Inflamm (Lond)"},{"issue":"2","key":"9882_CR45","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ajpath.2012.10.014","volume":"182","author":"S Guo","year":"2013","unstructured":"Guo S, et al. Lipopolysaccharide causes an increase in intestinal tight junction permeability in vitro and in vivo by inducing enterocyte membrane expression and localization of TLR-4 and CD14. Am J Pathol 2013;182(2):375\u2013387","journal-title":"Am J Pathol"},{"issue":"5","key":"9882_CR46","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/hep.23917","volume":"52","author":"JP Nolan","year":"2010","unstructured":"Nolan JP. The role of intestinal endotoxin in liver injury: a long and evolving history. Hepatology 2010;52(5):1829\u20131835","journal-title":"Hepatology"},{"issue":"12","key":"9882_CR47","doi-asserted-by":"publisher","first-page":"3338","DOI":"10.1111\/ajt.13963","volume":"16","author":"WG Land","year":"2016","unstructured":"Land WG, et al. Transplantation and damage-associated molecular patterns (DAMPs). Am J Transplant 2016;16(12):3338\u20133361","journal-title":"Am J Transplant"},{"key":"9882_CR48","doi-asserted-by":"publisher","first-page":"11653","DOI":"10.1038\/ncomms11653","volume":"7","author":"B van Wilgenburg","year":"2016","unstructured":"van Wilgenburg B, et al. MAIT cells are activated during human viral infections. Nat Commun 2016;7:11653","journal-title":"Nat Commun"},{"issue":"3","key":"9882_CR49","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.tem.2018.01.002","volume":"29","author":"AR Hamoud","year":"2018","unstructured":"Hamoud AR, et al. Bilirubin in the liver\u2013gut signaling axis. Trends Endocrinol Metab 2018;29(3):140\u2013150","journal-title":"Trends Endocrinol Metab"},{"issue":"4","key":"9882_CR50","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrgastro.2011.27","volume":"8","author":"NJ Wood","year":"2011","unstructured":"Wood NJ. IBD: stem cell therapy feasible, safe and beneficial for fistulizing Crohn\u2019s disease. Nat Rev Gastroenterol Hepatol 2011;8(4):181","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"9882_CR51","doi-asserted-by":"publisher","first-page":"a018341","DOI":"10.1101\/cshperspect.a018341","volume":"5","author":"OJ Harrison","year":"2013","unstructured":"Harrison OJ, Powrie FM. Regulatory T cells and immune tolerance in the intestine. Cold Spring Harb Perspect Biol 2013;5(7):a018341","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"9904","key":"9882_CR52","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/S0140-6736(13)60096-3","volume":"382","author":"GM Hirschfield","year":"2013","unstructured":"Hirschfield GM, et al. Primary sclerosing cholangitis. Lancet 2013;382(9904):1587\u20131599","journal-title":"Lancet"},{"issue":"6","key":"9882_CR53","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1136\/gut.2007.122168","volume":"57","author":"DH Adams","year":"2008","unstructured":"Adams DH, Eksteen B, Curbishley SM. Immunology of the gut and liver: a love\/hate relationship. Gut 2008;57(6):838\u2013848","journal-title":"Gut"},{"issue":"1","key":"9882_CR54","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1053\/j.gastro.2009.02.046","volume":"137","author":"B Eksteen","year":"2009","unstructured":"Eksteen B, et al. Gut homing receptors on CD8 T cells are retinoic acid dependent and not maintained by liver dendritic or stellate cells. Gastroenterology 2009;137(1):320\u2013329","journal-title":"Gastroenterology"},{"issue":"5802","key":"9882_CR55","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1126\/science.1132742","volume":"314","author":"JR Mora","year":"2006","unstructured":"Mora JR, et al. Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells. Science 2006;314(5802):1157\u20131160","journal-title":"Science"},{"key":"9882_CR56","doi-asserted-by":"publisher","first-page":"2097274","DOI":"10.1155\/2016\/2097274","volume":"2016","author":"FA Silva","year":"2016","unstructured":"Silva FA, et al. The immunological basis of inflammatory bowel disease. Gastroenterol Res Pract 2016;2016:2097274","journal-title":"Gastroenterol Res Pract"},{"issue":"5","key":"9882_CR57","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/mi.2015.49","volume":"8","author":"M Sun","year":"2015","unstructured":"Sun M, et al. Regulatory immune cells in regulation of intestinal inflammatory response to microbiota. Mucosal Immunol 2015;8(5):969\u2013978","journal-title":"Mucosal Immunol"},{"issue":"7","key":"9882_CR58","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.3748\/wjg.v22.i7.2195","volume":"22","author":"A Yamada","year":"2016","unstructured":"Yamada A, et al. Role of regulatory T cell in the pathogenesis of inflammatory bowel disease. World J Gastroenterol 2016;22(7):2195\u20132205","journal-title":"World J Gastroenterol"},{"issue":"1","key":"9882_CR59","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/imr.12039","volume":"252","author":"M Shale","year":"2013","unstructured":"Shale M, Schiering C, Powrie F. CD4(+) T-cell subsets in intestinal inflammation. Immunol Rev 2013;252(1):164\u2013182","journal-title":"Immunol Rev"},{"issue":"2","key":"9882_CR60","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jcmgh.2015.01.006","volume":"1","author":"P Kiesler","year":"2015","unstructured":"Kiesler P, Fuss IJ, Strober W. Experimental models of inflammatory bowel diseases. Cell Mol Gastroenterol Hepatol 2015;1(2):154\u2013170","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"4","key":"9882_CR61","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1136\/gutjnl-2014-306919","volume":"65","author":"JB Canavan","year":"2016","unstructured":"Canavan JB, et al. Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn\u2019s disease. Gut 2016;65(4):584\u2013594","journal-title":"Gut"},{"issue":"1","key":"9882_CR62","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s41598-018-19621-6","volume":"8","author":"JM Mathew","year":"2018","unstructured":"Mathew JM, et al. Generation and characterization of alloantigen-specific regulatory T cells for clinical transplant tolerance. Sci Rep 2018;8(1):1136","journal-title":"Sci Rep"},{"issue":"2","key":"9882_CR63","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/cei.12277","volume":"176","author":"NE Serriari","year":"2014","unstructured":"Serriari NE, et al. Innate mucosal-associated invariant T (MAIT) cells are activated in inflammatory bowel diseases. Clin Exp Immunol 2014;176(2):266\u2013274","journal-title":"Clin Exp Immunol"},{"issue":"7","key":"9882_CR64","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1097\/MIB.0000000000000397","volume":"21","author":"E Hiejima","year":"2015","unstructured":"Hiejima E, et al. Reduced numbers and proapoptotic features of mucosal-associated invariant T cells as a characteristic finding in patients with inflammatory bowel disease. Inflamm Bowel Dis 2015;21(7):1529\u20131540","journal-title":"Inflamm Bowel Dis"},{"key":"9882_CR65","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.coi.2013.09.007","volume":"26","author":"RW Birkinshaw","year":"2014","unstructured":"Birkinshaw RW, et al. MAITs, MR1 and vitamin B metabolites. Curr Opin Immunol 2014;26:7\u201313","journal-title":"Curr Opin Immunol"},{"issue":"10","key":"9882_CR66","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni.2416","volume":"13","author":"Y Lee","year":"2012","unstructured":"Lee Y, et al. Induction and molecular signature of pathogenic TH17 cells. Nat Immunol 2012;13(10):991\u2013999","journal-title":"Nat Immunol"},{"issue":"2","key":"9882_CR67","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1136\/gutjnl-2016-311915","volume":"66","author":"MN Quraishi","year":"2017","unstructured":"Quraishi MN, et al. The gut-adherent microbiota of PSC-IBD is distinct to that of IBD. Gut 2017;66(2):386\u2013388","journal-title":"Gut"},{"issue":"1","key":"9882_CR68","first-page":"3","volume":"34","author":"R Reantragoon","year":"2016","unstructured":"Reantragoon R, et al. Mucosal-associated invariant T cells in clinical diseases. Asian Pac J Allergy Immunol 2016;34(1):3\u201310","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"1 Pt 1","key":"9882_CR69","first-page":"G1","volume":"274","author":"M Salmi","year":"1998","unstructured":"Salmi M, Adams D, Jalkanen S. Cell adhesion and migration. IV. Lymphocyte trafficking in the intestine and liver. Am J Physiol 1998;274(1 Pt 1):G1\u2013G6","journal-title":"Am J Physiol"},{"issue":"6","key":"9882_CR70","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.jhep.2014.02.006","volume":"60","author":"P Fickert","year":"2014","unstructured":"Fickert P, et al. Characterization of animal models for primary sclerosing cholangitis (PSC). J Hepatol 2014;60(6):1290\u20131303","journal-title":"J Hepatol"},{"key":"9882_CR71","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3389\/fimmu.2015.00027","volume":"6","author":"E Treiner","year":"2015","unstructured":"Treiner E. Mucosal-associated invariant T cells in inflammatory bowel diseases: bystanders, defenders, or offenders? Front Immunol 2015;6:27","journal-title":"Front Immunol"},{"issue":"12","key":"9882_CR72","doi-asserted-by":"publisher","first-page":"e0188649","DOI":"10.1371\/journal.pone.0188649","volume":"12","author":"HC Jeffery","year":"2017","unstructured":"Jeffery HC, et al. Human intrahepatic ILC2 are IL-13positive amphiregulinpositive and their frequency correlates with model of end stage liver disease score. PLoS One 2017;12(12):e0188649","journal-title":"PLoS One"},{"key":"9882_CR73","doi-asserted-by":"publisher","unstructured":"Hunter S, et al. Human liver infiltrating \u03b3\u03b4 T cells are composed of clonally expanded circulating and tissue-resident populations. J Hepatol 201; pii:S0168-8278(18)32053-1. https:\/\/doi.org\/10.1016\/j.jhep.2018.05.007","DOI":"10.1016\/j.jhep.2018.05.007"},{"key":"9882_CR74","doi-asserted-by":"publisher","first-page":"2862173","DOI":"10.1155\/2016\/2862173","volume":"2016","author":"J Yu","year":"2016","unstructured":"Yu J, et al. The pathogenesis of nonalcoholic fatty liver disease: interplay between diet, gut microbiota, and genetic background. Gastroenterol Res Pract 2016;2016:2862173","journal-title":"Gastroenterol Res Pract"},{"issue":"4","key":"9882_CR75","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1159\/000456589","volume":"35","author":"SA Townsend","year":"2017","unstructured":"Townsend SA, Newsome PN. The role of a dedicated non-alcoholic fatty liver disease clinic in 2016. Dig Dis 2017;35(4):371\u2013376","journal-title":"Dig Dis"},{"issue":"12","key":"9882_CR76","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.1210\/jc.2006-0587","volume":"91","author":"KM Utzschneider","year":"2006","unstructured":"Utzschneider KM, Kahn SE. Review: the role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2006;91(12):4753\u20134761","journal-title":"J Clin Endocrinol Metab"},{"key":"9882_CR77","doi-asserted-by":"publisher","first-page":"5170402","DOI":"10.1155\/2016\/5170402","volume":"2016","author":"N Magee","year":"2016","unstructured":"Magee N, Zou A, Zhang Y. Pathogenesis of nonalcoholic steatohepatitis: interactions between liver parenchymal and nonparenchymal cells. Biomed Res Int 2016;2016:5170402","journal-title":"Biomed Res Int"},{"issue":"1","key":"9882_CR78","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cmet.2017.08.002","volume":"27","author":"VT Samuel","year":"2018","unstructured":"Samuel VT, Shulman GI. Nonalcoholic fatty liver disease as a nexus of metabolic and hepatic diseases. Cell Metab 2018;27(1):22\u201341","journal-title":"Cell Metab"},{"key":"9882_CR79","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.3389\/fimmu.2017.01889","volume":"8","author":"RE Wawman","year":"2017","unstructured":"Wawman RE, Bartlett H, Oo YH. Regulatory T cell metabolism in the hepatic microenvironment. Front Immunol 2017;8:1889","journal-title":"Front Immunol"},{"issue":"1","key":"9882_CR80","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4049\/jimmunol.1501175","volume":"196","author":"M Rau","year":"2016","unstructured":"Rau M, et al. Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis is marked by a higher frequency of Th17 cells in the liver and an increased Th17\/resting regulatory T cell ratio in peripheral blood and in the liver. J Immunol 2016;196(1):97\u2013105","journal-title":"J Immunol"},{"key":"9882_CR81","doi-asserted-by":"publisher","first-page":"490","DOI":"10.3389\/fimmu.2016.00490","volume":"7","author":"FC Paquissi","year":"2016","unstructured":"Paquissi FC. Immune imbalances in non-alcoholic fatty liver disease: from general biomarkers and neutrophils to interleukin-17 axis activation and new therapeutic targets. Front Immunol 2016;7:490","journal-title":"Front Immunol"},{"issue":"2","key":"9882_CR82","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1365-2567.2007.02651.x","volume":"122","author":"G Liu","year":"2007","unstructured":"Liu G, Zhao Y. Toll-like receptors and immune regulation: their direct and indirect modulation on regulatory CD4+ CD25+ T cells. Immunology 2007;122(2):149\u2013156","journal-title":"Immunology"},{"issue":"12","key":"9882_CR83","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/ni.3577","volume":"17","author":"VA Gerriets","year":"2016","unstructured":"Gerriets VA, et al. Foxp3 and Toll-like receptor signaling balance Treg cell anabolic metabolism for suppression. Nat Immunol 2016;17(12):1459\u20131466","journal-title":"Nat Immunol"},{"issue":"1","key":"9882_CR84","first-page":"1","volume":"1","author":"J Heinrichs","year":"2016","unstructured":"Heinrichs J, et al. Regulatory T-cell therapy for graft-versus-host disease. J Immunol Res Ther 2016;1(1):1\u201314","journal-title":"J Immunol Res Ther"},{"issue":"8","key":"9882_CR85","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/tri.12909","volume":"30","author":"M Romano","year":"2017","unstructured":"Romano M, et al. Treg therapy in transplantation: a general overview. Transpl Int 2017;30(8):745\u2013753","journal-title":"Transpl Int"},{"issue":"315","key":"9882_CR86","doi-asserted-by":"publisher","first-page":"315ra189","DOI":"10.1126\/scitranslmed.aad4134","volume":"7","author":"JA Bluestone","year":"2015","unstructured":"Bluestone JA, et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med 2015;7(315):315ra189","journal-title":"Sci Transl Med"},{"issue":"1","key":"9882_CR87","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.clim.2014.03.016","volume":"153","author":"N Marek-Trzonkowska","year":"2014","unstructured":"Marek-Trzonkowska N, et al. Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets\u2014results of one year follow-up. Clin Immunol 2014;153(1):23\u201330","journal-title":"Clin Immunol"},{"key":"9882_CR88","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.meegid.2018.01.015","volume":"59","author":"A Karkhah","year":"2018","unstructured":"Karkhah A, Javanian M, Ebrahimpour S. The role of regulatory T cells in immunopathogenesis and immunotherapy of viral infections. Infect Genet Evol 2018;59:32\u201337","journal-title":"Infect Genet Evol"},{"key":"9882_CR89","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/j.0105-2896.2006.00412.x","volume":"212","author":"BT Rouse","year":"2006","unstructured":"Rouse BT, Sarangi PP, Suvas S. Regulatory T cells in virus infections. Immunol Rev 2006;212:272\u2013286","journal-title":"Immunol Rev"},{"key":"9882_CR90","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/9780470697405.ch16","volume":"292","author":"S Gregori","year":"2008","unstructured":"Gregori S, Battaglia M, Roncarolo MG. Re-establishing immune tolerance in type 1 diabetes via regulatory T cells. Novartis Found Symp 2008;292:174\u2013183 discussion 183\u20136, 202\u20133","journal-title":"Novartis Found Symp"},{"issue":"4","key":"9882_CR91","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1172\/JCI82771","volume":"126","author":"KG MacDonald","year":"2016","unstructured":"MacDonald KG, et al. Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. J Clin Invest 2016;126(4):1413\u20131424","journal-title":"J Clin Invest"},{"key":"9882_CR92","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.3389\/fimmu.2017.01371","volume":"8","author":"M Wiesinger","year":"2017","unstructured":"Wiesinger M, et al. Good manufacturing practice-compliant production and lot-release of ex vivo expanded regulatory T cells as basis for treatment of patients with autoimmune and inflammatory disorders. Front Immunol 2017;8:1371","journal-title":"Front Immunol"},{"issue":"9","key":"9882_CR93","doi-asserted-by":"publisher","first-page":"e3161","DOI":"10.1371\/journal.pone.0003161","volume":"3","author":"JH Peters","year":"2008","unstructured":"Peters JH, et al. Clinical grade Treg: GMP isolation, improvement of purity by CD127 depletion, Treg expansion, and Treg cryopreservation. PLoS One 2008;3(9):e3161","journal-title":"PLoS One"},{"issue":"8","key":"9882_CR94","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1182\/blood-2015-06-653667","volume":"127","author":"CG Brunstein","year":"2016","unstructured":"Brunstein CG, et al. Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. Blood 2016;127(8):1044\u20131051","journal-title":"Blood"},{"issue":"3","key":"9882_CR95","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/cei.12940","volume":"188","author":"HC Jeffery","year":"2017","unstructured":"Jeffery HC, et al. Low-dose interleukin-2 promotes STAT-5 phosphorylation, Treg survival and CTLA-4-dependent function in autoimmune liver diseases. Clin Exp Immunol 2017;188(3):394\u2013411","journal-title":"Clin Exp Immunol"},{"issue":"179","key":"9882_CR96","doi-asserted-by":"publisher","first-page":"179ra43","DOI":"10.1126\/scitranslmed.3005265","volume":"5","author":"K Matsuoka","year":"2013","unstructured":"Matsuoka K, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med 2013;5(179):179ra43","journal-title":"Sci Transl Med"},{"issue":"22","key":"9882_CR97","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","volume":"365","author":"J Koreth","year":"2011","unstructured":"Koreth J, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011;365(22):2055\u20132066","journal-title":"N Engl J Med"},{"issue":"27","key":"9882_CR98","doi-asserted-by":"publisher","first-page":"7083","DOI":"10.1073\/pnas.1620835114","volume":"114","author":"G Whitehouse","year":"2017","unstructured":"Whitehouse G, et al. IL-2 therapy restores regulatory T-cell dysfunction induced by calcineurin inhibitors. Proc Natl Acad Sci USA 2017;114(27):7083\u20137088","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"9882_CR99","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1038\/ni.1774","volume":"10","author":"X Zhou","year":"2009","unstructured":"Zhou X, et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol 2009;10(9):1000\u20131007","journal-title":"Nat Immunol"},{"issue":"4","key":"9882_CR100","doi-asserted-by":"publisher","first-page":"e1373208","DOI":"10.1080\/21688370.2017.1373208","volume":"5","author":"T Takiishi","year":"2017","unstructured":"Takiishi T, Fenero CIM, Camara NOS. Intestinal barrier and gut microbiota: shaping our immune responses throughout life. Tissue Barriers 2017;5(4):e1373208","journal-title":"Tissue Barriers"}],"updated-by":[{"DOI":"10.1007\/s12072-022-10397-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000}}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-018-9882-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-018-9882-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-018-9882-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T21:03:56Z","timestamp":1693775036000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-018-9882-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":100,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["9882"],"URL":"https:\/\/doi.org\/10.1007\/s12072-018-9882-x","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s12072-022-10397-6","asserted-by":"object"}]},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"9 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12072-022-10397-6","URL":"https:\/\/doi.org\/10.1007\/s12072-022-10397-6","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}}]}}